Although overactive bladder (OAB) and detrusor overactivity (DO) are not synonyms, they share therapeutic options and partially underlying physiopathological mechanisms. The aim of this overview is to give insight into new potential targets for the treatment of OAB and DO. A narrative review was done in order to reach this goal. Ageing, pelvic floor disorders, hypersensitivity disorders, morphologic bladder changes, neurological diseases, local inflammations, infections, tumors and bladder outlet obstruction may alter the normal voluntary control of micturition, leading to OAB and DO. The main aim of pharmacotherapy is to restore normal control of micturition, inhibiting the emerging pathological involuntary reflex mechanism. Therapeutic targets can be found at the levels of the urothelium, detrusor muscles, autonomic and afferent pathways, spinal cord and brain. Increased expression and/or sensitivity of urothelial-sensory molecules that lead to afferent sensitization have been documented as a possible pathogenesis of OAB. Targeting afferent pathways and/or bladder smooth muscles by modulating activity of ligand receptors and ion channels could be effective to suppress OAB.

Keywords:
Bladder dysfunction, Overactive bladder, Detrusor overactivity, Therapy, Urothelium
1.
Abrams PA, Cardozo L, Fall M, et al: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21:167–178.
2.
Birder L, Drake M, Fowler C, et al: Neural control; in Abrams P, Khoury S, Wein A (eds): Incontinence: 4th International Consultation on Incontinence. Paris, Health Publications Ltd, 2009, pp 167–254.
3.
Koelbl H, Nitti V, Baessler K, et al: Pathophysiology of urinary incontinence, faecal incontinence and pelvic organ prolapse; in Abrams P, Khoury S, Wein A (eds): Incontinence: 4th International Consultation on Incontinence. Paris, Health Publications Ltd, 2009, pp 255–330.
4.
Wein AJ, Rackley RR: Overactive bladder: a better understanding of pathophysiology, diagnosis and management. J Urol 2006;175:S5–S10.
5.
Andersson KE: Antimuscarinics for the treatment of overactive bladder. Lancet Neurol 2004;3:46–53.
6.
Andersson KE, Chapple CR, Cardozo L, et al: Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol 2009;19:380–394.
7.
Andersson KE, Chapple CR, Cardozo L, et al: Pharmacological treatment of urinary Incontinence; in Abrams P, Khoury S, Wein A (eds): Incontinence: 4th International Consultation on Incontinence. Paris, Health Publications Ltd, 2009, pp 631–700.
8.
Yoshimura N, Kaiho Y, Miyazato M, et al: Therapeutic receptor targets for lower urinary tract dysfunction. Naunyn Schmiedebergs Arch Pharmacol 2008;377:437–448.
9.
Eglen RM: Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Auton Autacoid Pharmacol 2006;26:219–233.
10.
Yamaguchi O: Antimuscarinics and overactive bladder: other mechanism of action. Neurourol Urodyn 2010;29:112–115.
11.
Yoshida M, Inadome A, Maeda Y, et al: Non-neuronal cholinergic system in human bladder urothelium. Urology 2006;67:425–430.
12.
Mansfield KJ, Liu L, Mitchelson FJ, et al: Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol 2005;144:1089–1099.
13.
Mukerji G, Yiangou Y, Grogono J, et al: Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol 2006;176:367–373.
14.
Ohtake A, Sato S, Sasamata M, Miyata K: The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially urgency episodes. Pharmacol Sci 2010;112:135–141.
15.
Birder LA, Barrick SR, Roppolo JR, et al: Feline interstitial cystitis results in mechanical hypersensitivity and altered ATP release from bladder urothelium. Am J Physiol Renal Physiol 2003;285:F423–F429.
16.
Fry CH, Sui GP, Kanai AJ, Wu C: The function of suburothelial myofibroblasts in the bladder. Neurourol Urodyn 2007;26(suppl 6):914–919.
17.
Downie JW, Armour JA: Mechanoreceptor afferent activity compared with receptor field dimensions and pressure changes in feline urinary bladder. Can J Physiol Pharmacol 1992;70:1457–1467.
18.
Nandigama R, Bonitz M, Papadakis T, et al: Muscarinic acetylcholine receptor subtypes expressed by mouse bladder afferent neurons. Neuroscience 2010;168:842–850.
19.
Matsumoto Y, Miyazato M, Furuta A, et al: Differential roles of M2 and M3 muscarinic receptor subtypes in modulation of bladder afferent activity in rats. Urology 2010;75:862–867.
20.
Daly DM, Chess-Williams R, Chapple C, Grundy D: The inhibitory role of acetylcholine and muscarinic receptors in bladder afferent activity. Eur Urol 2010;58:22–28.
21.
Peretto I, Petrillo P, Imbimbo BP: Medicinal chemistry and therapeutic potential of muscarinic M3 antagonists. Med Res Rev 2009;29:867–902.
22.
Sun B, Li Q, Dong L, Rong W: Ion channel and receptor mechanisms of bladder afferent nerve sensitivity. Auton Neurosci 2010;153:26–32.
23.
Werner ME, Knorn AM, Meredith AL, et al: Frequency encoding of cholinergic- and purinergic-mediated signaling to mouse urinary bladder smooth muscle: modulation by BK channels. Am J Physiol Regul Integr Comp Physiol 2007;292:R616–R624.
24.
Darblade B, Behr-Roussel D, Oger S, et al: Effects of potassium channel modulators on human detrusor smooth muscle myogenic phasic contractile activity: potential therapeutic targets for overactive bladder. Urology 2006;68:442–448.
25.
Shieh CC, Brune ME, Buckner SA, et al: Characterization of a novel ATP-sensitive K+ channel opener, A-251179, on urinary bladder relaxation and cystometric parameters. Br J Pharmacol 2007;151:467–475.
26.
Gopalakrishnan M, Buckner SA, Shieh CC, et al: In vitro and in vivo characterization of a novel naphthylamide ATP-sensitive K+ channel opener, A-151892. Br J Pharmacol 2004;143:81–90.
27.
Kamiyama Y, Muto S, Masuda H, et al: Inhibitory effects of nicorandil, a K ATP channel opener and a nitric oxide donor, on overactive bladder in animal models. BJU Int 2008;101:360–365.
28.
Yunoki T, Zhu HL, Iwasa K, et al: Comparative studies of ZD0947, a novel ATP-sensitive K(+) channel opener, on guinea pig detrusor and aortic smooth muscles. Naunyn Schmiedebergs Arch Pharmacol 2008;376:309–319.
29.
Chapple CR, Patroneva A, Raines SR: Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: a randomized, double-blind, placebo-controlled study (ZD0947IL/0004). Eur Urol 2006;49:879–886.
30.
Araki I, Du S, Kobayashi H, et al: Roles of mechanosensitive ion channels in bladder sensory transduction and overactive bladder. Int J Urol 2008;15:681–687.
31.
Everaerts W, Gevaert T, Nilius B, De Ridder D: On the origin of bladder sensing: tr(i)ps in urology. Neurourol Urodyn 2008;27:264–273.
32.
Mukerji G, Yiangou Y, Corcoran SL, et al: Cool and menthol receptor TRPM8 in human urinary bladder disorders and clinical correlations. BMC Urol 2006;6:6.
33.
Lashinger ES, Steiginga MS, Hieble JP, et al: AMTB, a TRPM8 channel blocker: evidence in rats for activity in overactive bladder and painful bladder syndrome. Am J Physiol Renal Physiol 2008;295:F803–F810.
34.
Imamura T, Ishizuka O, Zhong C, et al: An extract (THC-002) of Ba-Wei-Die-Huang-Wan inhibits expression of tachykinins, and P2X3 and TRPV1 receptors, and inhibits ATP-induced detrusor overactivity in spontaneously hypertensive rats. Neurourol Urodyn 2009;28:529–534.
35.
Imamura T, Ishizuka O, Aizawa N, et al: Gosha-jinki-gan reduces transmitter proteins and sensory receptors associated with C fiber activation induced by acetic acid in rat urinary bladder. Neurourol Urodyn 2008;27:832–837.
36.
Cruz CD, Charrua A, Vieira E, et al: Intrathecal delivery of resiniferatoxin (RTX) reduces detrusor overactivity and spinal expression of TRPV1 in spinal cord injured animals. Exp Neurol 2008;214:301–308.
37.
Wiseman OJ, Fowler CJ, Landon DN: The role of the human bladder lamina propria myofibroblast. BJU Int 2003;91:89–93.
38.
Sui GP, Rothery S, Dupont E, et al: Gap junctions and connexin expression in human suburothelial interstitial cells. BJU Int 2002;90:118–129.
39.
Sui GP, Wu C, Fry CH: Characterization of the purinergic receptor subtype on guinea-pig suburothelial myofibroblasts. BJU Int 2006;97:327–331.
40.
Pannek J, Janek S, Sommerer F, Tannapfel A: Expression of purinergic P2X2-receptors in neurogenic bladder dysfunction due to spinal cord injury: a preliminary immunohistochemical study. Spinal Cord 2009;47:561–564.
41.
Kaan TK, Yip PK, Grist J, et al: Endogenous purinergic control of bladder activity via presynaptic P2X3 and P2X2/3 receptors in the spinal cord. J Neurosci 2010;30:4503–4507.
42.
Michel MC, Sand C: Effect of pre-contraction on beta-adrenoceptor-mediated relaxation of rat urinary bladder. World J Urol 2009;27:711–715.
43.
De Groat WC, Booth AM, Yoshimura N: Neurophysiology of micturition and its modification in animal models of human disease; in Maggi CA (eds): The Autonomic Nervous System. Vol. 6. Nervous Control of the Urogenital System. London, Harwood Academic Publisher, 1993, pp 227–289.
44.
McMahon SB, Spillane K: Brain stem influences on the parasympathetic supply to the urinary bladder in the cat. Brain Res 1982;234:237–249.
45.
Sugaya K, Ogawa Y, Hatano T, et al: Evidence for involvement of the subcoeruleus nucleus raphe magnus in urine storage and penile erection in decerebrate rats. J Urol 1998;159:2172–2176.
46.
Khaled SM, Elhilali M: Role of 5-HT receptors in treatment of overactive bladder. Drugs Today (Barc) 2003;39:599–607.
47.
Steers WD, Clemow DB, Persson K, et al: The spontaneously hypertensive rat: insight into the pathogenesis of irritative symptoms in benign prostatic hyperplasia and young anxious males. Exp Physiol 1999;84:137–147.
48.
Persson K, Pandita RK, Spitsbergen JM, et al: Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats. Am J Physiol 1998;275(4 Pt 2):R1366–R1373.
49.
Kontani H, Tsuji T, Kimura S: Effects of adrenergic alpha2 receptor agonists on urinary bladder contraction in conscious rats. Jpn J Pharmacol 2000;84:381–390.
50.
Rickenbacher E, Baez MA, Hale L, et al: Impact of overactive bladder on the brain: central sequelae of a visceral pathology. Proc Natl Acad Sci USA 2008;105:10589–10594.
51.
Aubel B, Kayser V, Farre A, et al: Evidence for adenosine- and serotonin-mediated antihyperalgesic effects of cizolirtine in rats suffering from diabetic neuropathy. Neuropharmacology 2007;52:487–496.
52.
Aubel B, Kayser V, Mauborgne A, et al: Antihyperalgesic effects of cizolirtine in diabetic rats: behavioural and biochemical studies. Pain 2004;110:22–32.
53.
Ballet S, Aubel B, Mauborgne A, et al: The novel analgesic, cizolirtine, inhibits the spinal release of substance P and CGRP in rats. Neuropharmacology 2001;40:578–589.
54.
Montier F, Caruette A, Moussaqui S, et al: Antagonism of substance P and related peptides by RP 67580 and CP-96,345, at tachykinin NK1 receptor sites, in the rat urinary bladder. Eur J Pharmacol 1994;251:9–14.
55.
Martìnez-García R, Abadías M, Arañó P, et al; for the ESCLIN 006/00 Study Group: Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study. Eur Urol 2009;56:184–192.
56.
Zát’ura F, Vsetica J, Abadías M, et al; for the E-4018/CL50 Study Group: Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study. Eur Urol 2010;57:145–152.
57.
Downie JW: Pharmacological manipulation of central micturition circuitry. Curr Opin CPNS Investig Drugs 1999;1:231–239.
58.
De Groat WC, Yoshimura N: Pharmacology of the lower urinary tract. Annu Rev Pharmacol Toxicol 2001;41:691–721.
59.
Yokohama O, Yoshiyama M, Namiki M, et al: Influence of anesthesia on bladder hyperactivity induced by middle cerebral artery occlusion in the rat. Am J Physiol 1997;273 (6 pt 2):R1900–R1907.
60.
Yokoyama O, Yoshiyama M, Namiki M, et al: Glutaminergic and dopaminergic contributions to rat bladder hyperactivity after cerebral artery occlusion. Am J Physiol 1999;276(4 pt 2):R935–R942.
61.
Kitta T, Kakizaki H, Tanaka H, et al: An alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate glutamate-receptor antagonist can inhibit premicturition contractions in rats with bladder outlet obstruction. BJU Int 2007;100:181–186.
62.
Chancellor MB, Fowler CJ, Apostolidis A, et al: Drug insight: biological effects of botulinum toxin A in the lower urinary tract. Nat Clin Pract Urol 2008;5:319–328.
63.
Lawrence GW, Aoki KR, Dolly JO: Excitatory cholinergic and purinergic signaling in bladder are equally susceptible to botulinum neurotoxin A consistent with co-release of transmitters from efferent fibers. J Pharmacol Exp Ther 2010;334:1080–1086.
64.
Schmid DM, Roy S, Sulser T, Scheiner D: Prospects and limitations of treatment with botulinum neurotoxin type A for patients with refractory idiopathic detrusor overactivity. BJU Int 2008;102(suppl 1):7–10.
65.
Apostolidis A, Dasgupta P, Denys P, et al: Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 2009;55:100–120.
66.
Caremel R, Oger-Roussel S, Behr-Roussel D, et al: Nitric oxide/cyclic guanosine monophosphate signalling mediates an inhibitory action on sensory pathways of the micturition reflex in the rat. Eur Urol 2010;58:616–625.
67.
Oger S, Behr-Roussel D, Gorny D, et al: Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle. Br J Pharmacol 2010;160:1135–1143.
68.
Liu HT, Chen CY, Kuo HC: Urinary nerve growth factor in women with overactive bladder syndrome. BJU Int 2011;107:799–803.
69.
Kuo HC, Liu HT, Chancellor MB: Can urinary nerve growth factor be a biomarker for overactive bladder? Rev Urol 2010;12:e69–e77.
70.
Kuo HC, Liu HT, Chancellor MB: Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence. Neurourol Urodyn 2010;29:482–487.
71.
Liu HT, Chancellor MB, Kuo HC: Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU Int 2009;103:1668–1672.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.